Health, Fitness & Food

Former US President and Republican presidential candidate Donald Trump speaks during a presidential debate with US Vice President and Democratic presidential candidate Kamala Harris at the National Constitution Center in Philadelphia, Pennsylvania, on September 10, 2024.  Saul Loeb | AFP | Getty Images The economic woes from inflation look to have accelerated a shift of
0 Comments
In this article BMY Follow your favorite stocksCREATE FREE ACCOUNT Bristol Myers Squibb’s Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb‘s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades.  Schizophrenia affects how
0 Comments
In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Novo Nordisk‘s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative
0 Comments
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.  Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Wegovy,
0 Comments
Getty Images Consumers may feel their medical bills are unyielding, inflexible, set in stone. But that’s not always true: A new study shows patients can often reap financial benefits by disputing charges that seem erroneous or by negotiating for financial relief. Of consumers who don’t reach out to question a medical bill, 86% said it’s
0 Comments
In this article ME Follow your favorite stocksCREATE FREE ACCOUNT Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023.  Jordan Vonderhaar | Bloomberg | Getty Images All seven independent directors of 23andMe resigned from the company’s board Tuesday,
0 Comments
In this article RHHBF Follow your favorite stocksCREATE FREE ACCOUNT Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.  Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to
0 Comments
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough.  Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceuticals makers. They’ve snapped up smaller upstarts to get their hands on technology that, while in its
0 Comments
In this article PFE Follow your favorite stocksCREATE FREE ACCOUNT Kena Betancur | Corbis News | Getty Images Pfizer‘s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday.  Patients with the condition, called cancer cachexia, who
0 Comments
In this article MRNA Follow your favorite stocksCREATE FREE ACCOUNT Moderna headquarters, exterior view, Cambridge, Massachusetts, USA.  Plexi Images | GHI | UCG | Universal Images Group | Getty Images Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a
0 Comments
Zoom In IconArrows pointing outwards Noom GLP-1 RX Courtesy of Noom Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.  The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs
0 Comments